Výsledky vyhledávání - "Cheng Cai Tang"

333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D)

Autor: CHARLES BENSON, LAI-SAN THAM, YU DU, SIREL GURBUZ, DEBORAH A. ROBINS, KIEREN J. MATHER, CHENG CAI TANG, MELISSA K. THOMAS

Publikováno v: Diabetes. 71

LY is an acylated peptide analog of oxyntomodulin, a dual glucagon and GLP-1 receptor agonist. We conducted 2 randomized, double-blind, phase 1 multiple ascending subcutaneous dosing studies in healthy subjects (S1, NCT03325387) and in T2D patients (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da6546f5511140d04601d7757016dbef
https://doi.org/10.2337/db22-333-or

Zobrazit plný text záznamu

A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide

Autor: Kashif M. Munir, Kathleen Dungan, Manige Konig, Lai San Tham, Anita Y. M. Kwan, Cheng Cai Tang, Kevin M. Pantalone

Publikováno v: Diabetes, obesitymetabolism. 24(2)

Aims To evaluate HbA1c and body weight changes when semaglutide 0.5 mg or 1.0 mg once weekly (QW) is switched to dulaglutide 3.0 mg or 4.5 mg QW via exposure-response modelling. Materials and methods HbA1c and body weight time-course models were deve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::533b24383d09c527afa144c616d53dd0
https://pubmed.ncbi.nlm.nih.gov/34697882

Zobrazit plný text záznamu

643-P: A Model-Based Evaluation of Glycemic and Weight Changes When Switching from Semaglutide to Additional Doses of Dulaglutide

Autor: Manige Konig, Kathleen Dungan, Kevin M. Pantalone, Kashif M. Munir, Cheng Cai Tang, Anita Kwan, Lai-San Tham

Publikováno v: Diabetes. 70

Dulaglutide 3.0 and 4.5 mg subcutaneous (SC) once weekly (QW) doses are approved for glycemic control in patients with type 2 diabetes (T2D). Using pharmacokinetic/pharmacodynamic models built from and validated with published data from SUSTAIN 1 to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3ffa2aa05afa08492a68fea50110a1e
https://doi.org/10.2337/db21-643-p

Zobrazit plný text záznamu

642-P: A Model-Based Evaluation of Nausea and Vomiting Events for Additional Doses of Dulaglutide in Existing and Dulaglutide-Naïve Patients with Type 2 Diabetes

Autor: Lai-San Tham, Heike Jung, Li Shen Loo, Cheng Cai Tang, Manige Konig, Jean S.K. Lim

Publikováno v: Diabetes. 70

Dulaglutide (DU) 3 mg and 4.5 mg once weekly (QW) doses were recently approved for additional glycemic control in adult patients with type 2 diabetes. If needed, a dose-escalation scheme from 1.5 mg to 3 mg and then 4.5 mg can be applied after at lea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::93b7957d961ad9b0b599e4f628705739
https://doi.org/10.2337/db21-642-p

Zobrazit plný text záznamu

106-OR: A First-in-Human Single Ascending Dose Study of Oxyntomodulin Analog LY3305677 in Healthy Subjects

Autor: Lai-San Tham, Cheng Cai Tang, Corina Loghin, Ross Bray, Melissa K. Thomas, Charles Benson

Publikováno v: Diabetes. 70

LY3305677 (LY) is an acylated single chain peptide analog of mammalian oxyntomodulin designed for once weekly dosing. It has dual pharmacology of GLP-1 and glucagon and has therapeutic potential for T2D, obesity and NASH. This randomized, double blin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71117499ba755b35c45ef5ab307889bb
https://doi.org/10.2337/db21-106-or

Zobrazit plný text záznamu

943-P: Role of Model-Informed Drug Development in Confirming Additional Clinical Benefits of Dulaglutide

Autor: Angelyn Bethel, David A. Cox, Cheng Cai Tang, Lai-San Tham, Karen Schneck, Jeanne Geiser, Zvonko Milicevic

Publikováno v: Diabetes. 69

Throughout the development cycle of dulaglutide, model-informed drug development (MIDD) was applied to facilitate and accelerate decision-making. Currently, dulaglutide 0.75 mg and 1.5 mg given subcutaneously once weekly (QW) is approved for the trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f7d42111e7c85fc345c444943fe3266
https://doi.org/10.2337/db20-943-p

Zobrazit plný text záznamu

Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates

Autor: Chuan Poh Lim, Sheng-Hsuan Tseng, Paul C. Ho, Sing Teang Kong, Cheng Cai Tang, Qi Chen

Publikováno v: Antimicrobial Agents and Chemotherapy. 62

Bacterial sepsis is a major cause of morbidity and mortality in neonates, especially those involving methicillin-resistant Staphylococcus aureus (MRSA). Guidelines by the Infectious Diseases Society of America recommend the vancomycin 24-h area under

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::458f66c316ea05b36001aaacd1154585
https://doi.org/10.1128/aac.01647-17

Zobrazit plný text záznamu

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

Autor: Yan Huang, Cheng Cai Tang, Paul G. Wakim, Gina A. Montealegre Sanchez, William L. Macias, Wanxia Li Tsai, Apurva Prakash, Stephen R. Brooks, Hanna Kim, Massimo Gadina, Raphaela Goldbach-Mansky, Adriana Almeida de Jesus, Kristina M Brooks, Jonathan Janes, Parag Kumar, Xin Zhang, Mary Blake

Publikováno v: Clinical pharmacology and therapeutics. 104(2)

Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral Janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a compassionate use program. Patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14cebcecffa3ef59ca624f98e01cae9b
https://pubmed.ncbi.nlm.nih.gov/29134648

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání